Coeptis Therapeutics Holdings Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
ZSQR$2.30-17.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended | ||
|---|---|---|
| September 30, 2024 | September 30, 2023 | |
| OPERATING ACTIVITIES | ||
| Net loss | $(7,865,647) | $(17,510,948) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Depreciation and amortization | 750,633 | 750,927 |
| Amortization of debt discount | 150,000 | – |
| Right of use asset amortization | 28,018 | 30,238 |
| Change in fair value of derivative liability warrants | (235,125) | (746,625) |
| Stock based compensation | 805,347 | 348,993 |
| Shares issued for non-employee services | 1,149,600 | 3,999,614 |
| Warrants issued for services | 8,150 | 2,438,026 |
| Loss on shares issued for conversion of debt | 77,250 | – |
| Shares issued in connection with asset purchase agreement | – | 4,320,000 |
| (Increase) decrease in: | ||
| Accounts receivable | – | 8,075 |
| Interest receivable | (152,104) | (833) |
| Prepaid assets | 156,880 | 76,724 |
| Right of use liability | (28,157) | (30,861) |
| Increase (decrease) in: | ||
| Accounts payable | (285,456) | 382,983 |
| Accrued expenses | 227,868 | 387,961 |
| NET CASH USED IN OPERATING ACTIVITIES | (5,212,743) | (5,545,728) |
| INVESTING ACTIVITIES | ||
| Increase in subscription receivable in exchange for cash | (100,000) | – |
| NET CASH USED IN INVESTING ACTIVITIES | (100,000) | – |
| FINANCING ACTIVITIES | ||
| Preferred stock offering | 3,218,561 | – |
| Proceeds from issuance of common stock and warrants, net of issuance costs | – | 3,040,935 |
| Proceeds from note payable | 1,850,000 | 500,000 |
| Repayment of notes payable, net of proceeds | (587,500) | (874,999) |
| Shares issued for cash | – | 500,000 |
| Warrants issued for cash | 500,000 | – |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 4,981,061 | 3,165,936 |
| NET DECREASE IN CASH | (331,682) | (2,379,792) |
| CASH AT BEGINNING OF PERIOD | 1,469,134 | 3,791,302 |
| CASH AT END OF PERIOD | $1,137,453 | $1,411,510 |
| SUPPLEMENTAL CASH FLOW DISCLOSURES | ||
| Interest paid | $– | $– |
| Taxes paid (refunded) | $– | $– |
| SUPPLEMENTAL NON-CASH DISCLOSURES | ||
| Warrants issued in exchange for subscriptions receivable | $2,000,000 | $2,500,000 |
| Preferred stock issued in exchange for subscriptions receivable | $2,100,000 | $– |
| Shares issued for the conversion of debt | $868,750 | $302,926 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.